Ketamine-induced schizophrenia animal model and mechanism study

Abstract

The present invention provides a ketamine-induced schizophrenia animal model and mechanism study. The study includes the following steps: 1) ketamine-induced schizophrenia animal model establishment;2) behavioral and morphological observation after ketamine-induced schizophrenia; 3) correlation with oxidative stress after ketamine-induced schizophrenia. Systemic observations are carried out on schizophrenia-like symptoms caused by single- or continuous-dose administration of small, medium, and large doses of ketamine to mice, the feasibility of establishing models of different doses and different administration ways is subjected to comparison and preliminary evaluation, and results show that single- or continuous-dose administration of ketamine can induce symptoms similar to schizophreniain mice and lead to a dose-dependent trend to a certain extent. In addition, through analysis, oxidative stress is correlative after ketamine-induced symptoms similar to schizophrenia of mice are developed, and a basis for study on subsequent ketamine addiction mechanism and schizophrenia is provided.

Description

technical field [0001] The invention relates to the technical field of animal models, in particular to a ketamine-induced schizophrenia animal model and the research on its mechanism. Background technique [0002] Ketamine (Ketamine, K) is a phencyclidine (phencylidine, PCP) derivative and a non-competitive N-methyl-D-aspartate (N-Methyl-D-Aspartate, NMDA) receptor antagonist. Ketamine has been used clinically as an intravenous anesthetic since 1970. Ketamine has two optical isomers, left-handed and right-handed, of which the right-handed isomer has a higher therapeutic index and fewer adverse reactions. Ketamine currently used clinically is a racemate of two enantiomers of dex-ketamine and L-ketamine. [0003] Ketamine is the only NMDA receptor antagonist approved by the U.S. Food and Drug Administration (FDA), and its mechanism of action is complex, involving NMDA receptors, opioid receptors, monoamine receptors, and acetylcholine receptors. and voltage-gated calcium ch...

AI Technical Summary

Problems solved by technology

[0007] The etiology of schizophrenia is unknown, and there are few studies on its pathogenesis at present. The clinical diagnosis mainly depends on the judgment of positive symptoms and negative symptoms, and there is a lack of objective biological detection indicators. Its treatment has always been a difficult problem in the medical field. Therefore, it is particularly important to establish experimental animal models of schizophrenia.